Celltrion’s novel coronavirus infection (Corona 19) antibody treatment’CT-P59′ / Yonhap News
Celltrion(355,000 +2.16%)On this coming 13th, the results of the global clinical phase 2 of the corona 19 antibody treatment’CT-P59′ (ingredient name regdanvimab) will be revealed.
According to Celltrion on the 5th, the company will announce the results of phase 2 of CT-P59 on the 13th, the first day of the conference, at the ‘2021 High1 New Drug Development Symposium’ hosted by the Korean Pharmaceutical Association. The presenter and the order of presentation have not been decided yet.
The 2021 High1 Drug Development Symposium will be held from the 13th to the 15th.
The CT-P59 phase 2 clinical trial was conducted in 327 mild and moderate corona19 patients in Korea, Romania, Spain and the United States. Celltrion completed phase 2 clinical trials of CT-P59 in November of last year and applied for conditional approval from the Ministry of Food and Drug Safety on the 29th of last month.
Celltrion has continued consultations with the government to announce the results of phase 2 clinical trials as soon as possible.
An official of the company said, “As it is clinical data, we had a plan to disclose it through the conference. We will announce it at the High1 New Drug Development Symposium, which can be announced at the earliest time.”
Celltrion plans to present the results of phase 2 clinical trials of CT-P59 at international conferences.
Reporter Park In-hyuk [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution